BACKGROUND AND AIMS: The Wnt/β-catenin signaling pathway has a well-described role in liver pathobiology. Its suppression was recently shown to decrease bile acid (BA) synthesis, thus preventing the development of cholestatic liver injury and fibrosis after bile duct ligation (BDL). APPROACH AND RESULTS: To generalize these observations, we suppressed β-catenin in Mdr2 knockout (KO) mice, which develop sclerosing cholangitis due to regurgitation of BA from leaky ducts. When β-catenin was knocked down (KD) in KO for 2 weeks, hepatic and biliary injury were exacerbated in comparison to KO given placebo, as shown by serum biochemistry, ductular reaction, inflammation, and fibrosis. Simultaneously, KO/KD livers displayed increased oxidative stress and senescence and an impaired regenerative response. Although the total liver BA levels were similar between KO/KD and KO, there was significant dysregulation of BA transporters and BA detoxification/synthesis enzymes in KO/KD compared with KO alone. Multiphoton intravital microscopy revealed a mixing of blood and bile in the sinusoids, and validated the presence of increased serum BA in KO/KD mice. Although hepatocyte junctions were intact, KO/KD livers had significant canalicular defects, which resulted from loss of hepatocyte polarity. Thus, in contrast to the protective effect of β-catenin KD in BDL model, β-catenin KD in Mdr2 KO aggravated rather than alleviated injury by interfering with expression of BA transporters, hepatocyte polarity, canalicular structure, and the regenerative response. CONCLUSIONS: The resulting imbalance between ongoing injury and restitution led to worsening of the Mdr2 KO phenotype, suggesting caution in targeting β-catenin globally for all cholestatic conditions.
BACKGROUND AND AIMS: The Wnt/β-catenin signaling pathway has a well-described role in liver pathobiology. Its suppression was recently shown to decrease bile acid (BA) synthesis, thus preventing the development of cholestatic liver injury and fibrosis after bile duct ligation (BDL). APPROACH AND RESULTS: To generalize these observations, we suppressed β-catenin in Mdr2 knockout (KO) mice, which develop sclerosing cholangitis due to regurgitation of BA from leaky ducts. When β-catenin was knocked down (KD) in KO for 2 weeks, hepatic and biliary injury were exacerbated in comparison to KO given placebo, as shown by serum biochemistry, ductular reaction, inflammation, and fibrosis. Simultaneously, KO/KD livers displayed increased oxidative stress and senescence and an impaired regenerative response. Although the total liver BA levels were similar between KO/KD and KO, there was significant dysregulation of BA transporters and BA detoxification/synthesis enzymes in KO/KD compared with KO alone. Multiphoton intravital microscopy revealed a mixing of blood and bile in the sinusoids, and validated the presence of increased serum BA in KO/KD mice. Although hepatocyte junctions were intact, KO/KD livers had significant canalicular defects, which resulted from loss of hepatocyte polarity. Thus, in contrast to the protective effect of β-catenin KD in BDL model, β-catenin KD in Mdr2 KO aggravated rather than alleviated injury by interfering with expression of BA transporters, hepatocyte polarity, canalicular structure, and the regenerative response. CONCLUSIONS: The resulting imbalance between ongoing injury and restitution led to worsening of the Mdr2 KO phenotype, suggesting caution in targeting β-catenin globally for all cholestatic conditions.
Authors: Lili Zhou; Tirthadipa Pradhan-Sundd; Minakshi Poddar; Sucha Singh; Alex Kikuchi; Donna B Stolz; Weinian Shou; Zongfang Li; Kari N Nejak-Bowen; Satdarshan P Monga Journal: Am J Pathol Date: 2015-10-17 Impact factor: 4.307
Authors: James H Tabibian; Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso Journal: Hepatology Date: 2014-04-25 Impact factor: 17.425
Authors: B Goodwin; S A Jones; R R Price; M A Watson; D D McKee; L B Moore; C Galardi; J G Wilson; M C Lewis; M E Roth; P R Maloney; T M Willson; S A Kliewer Journal: Mol Cell Date: 2000-09 Impact factor: 17.970
Authors: Peter Fickert; Gernot Zollner; Andrea Fuchsbichler; Conny Stumptner; Andreas H Weiglein; Frank Lammert; Hanns-Ulrich Marschall; Oleksiy Tsybrovskyy; Kurt Zatloukal; Helmut Denk; Michael Trauner Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Grace L Guo; Gilles Lambert; Masahiko Negishi; Jerrold M Ward; H Bryan Brewer; Steven A Kliewer; Frank J Gonzalez; Christopher J Sinal Journal: J Biol Chem Date: 2003-08-15 Impact factor: 5.157
Authors: Thomas G Bird; Miryam Müller; Luke Boulter; David F Vincent; Rachel A Ridgway; Elena Lopez-Guadamillas; Wei-Yu Lu; Thomas Jamieson; Olivier Govaere; Andrew D Campbell; Sofía Ferreira-Gonzalez; Alicia M Cole; Trevor Hay; Kenneth J Simpson; William Clark; Ann Hedley; Mairi Clarke; Pauline Gentaz; Colin Nixon; Steven Bryce; Christos Kiourtis; Joep Sprangers; Robert J B Nibbs; Nico Van Rooijen; Laurent Bartholin; Steven R McGreal; Udayan Apte; Simon T Barry; John P Iredale; Alan R Clarke; Manuel Serrano; Tania A Roskams; Owen J Sansom; Stuart J Forbes Journal: Sci Transl Med Date: 2018-08-15 Impact factor: 17.956